TransMedics Group, Inc. (TMDX) Financial Statements
Industry: Electromedical & Electrotherapeutic Apparatus
In fiscal 2025, TransMedics reported revenue of $605.5M, up 37.1% from $441.5M the year before. Net income was $190.3M (a 31.4% net margin), or $4.87 per diluted share. Gross margin was 59.9% and operating margin was 17.9%. Operating activities generated $192.8M of cash, leaving $133.6M of free cash flow. At fiscal year end, TransMedics held $1.07B in total assets against $595.3M in total liabilities.
Open the full interactive TransMedics financials → Quarterly statements, key ratios, valuation history and price charts.
TransMedics Key Stats
| Share Price | $79.14 |
|---|---|
| Market Cap | $3.22B |
| P/E Ratio | 16.2 |
| Revenue YoY Growth | +37.1% |
| 52-Week Range | $62.04 – $150.42 |
| Shares Outstanding | 34.6 million (basic, 2026 Q2) |
TransMedics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $25.6M | $30.3M | $93.5M | $241.6M | $441.5M | $605.5M |
| Gross Profit | — | $21.2M | $65.3M | $154.1M | $262.1M | $362.8M |
| Operating Income | -$26.4M | -$39.4M | -$31.4M | -$28.7M | $37.5M | $108.6M |
| Pre-Tax Income | -$28.7M | -$44.2M | -$36.2M | -$26.7M | $35.8M | $107.5M |
| Income Tax | $0 | $36,000 | $66,000 | -$1.7M | $316,000 | -$82.8M |
| Net Income | -$28.7M | -$44.2M | -$36.2M | -$25.0M | $35.5M | $190.3M |
| Diluted EPS | -$1.16 | -$1.60 | -$1.23 | -$0.77 | $1.01 | $4.87 |
TransMedics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $143.8M | $160.8M | $173.9M | $189.9M |
| Net Income | $24.3M | $105.4M | $7.3M | $14.7M |
| Diluted EPS | $0.66 | $2.60 | $0.20 | $0.41 |
TransMedics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.6M | $25.6M | $201.2M | $394.8M | — | — |
| Current Assets | $146.8M | $118.7M | $252.3M | $510.7M | $497.2M | $637.8M |
| Total Assets | $152.0M | $134.9M | $277.1M | $706.0M | $804.1M | $1.07B |
| Current Liabilities | $11.9M | $23.2M | $23.7M | $54.9M | $59.9M | $89.3M |
| Total Long-Term Debt | $34.7M | $35.2M | $58.7M | $506.2M | $509.3M | $512.4M |
| Total Liabilities | $48.1M | $67.0M | $89.8M | $568.8M | $575.5M | $595.3M |
| Shareholders' Equity | $103.9M | $67.9M | $187.4M | $137.2M | $228.6M | $473.1M |
TransMedics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.3M | -$28.9M | -$45.8M | -$13.0M | $48.8M | $192.8M |
| Cash From Investing | -$41.6M | $29.3M | $54.5M | -$194.0M | -$129.3M | -$59.3M |
| Cash From Financing | $75.5M | $1.4M | $167.9M | $400.4M | $22.9M | $16.9M |
| Free Cash Flow | -$30.7M | -$32.4M | -$57.7M | -$164.9M | -$80.9M | $133.6M |
Figures from TransMedics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full TransMedics financials page for every line item.
TransMedics Company Profile
| Ticker | TMDX |
|---|---|
| Exchange | Nasdaq |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Headquarters | Andover, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001756262 |
Frequently Asked Questions
What was TransMedics' revenue in fiscal 2025?
TransMedics (TMDX) reported revenue of $605.5M for fiscal 2025.
What is TransMedics' annual revenue history?
TransMedics' annual revenue by fiscal year: 2020: $25.6M; 2021: $30.3M; 2022: $93.5M; 2023: $241.6M; 2024: $441.5M; 2025: $605.5M.
What was TransMedics' net income in fiscal 2025?
TransMedics reported net income of $190.3M for fiscal 2025.
What was TransMedics' earnings per share (EPS) in fiscal 2025?
TransMedics' diluted EPS was $4.87 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did TransMedics generate in fiscal 2025?
TransMedics generated $133.6M of free cash flow in fiscal 2025.
What was TransMedics' revenue last quarter?
In its most recent reported quarter (2026 Q2), TransMedics reported revenue of $189.9M.
How much debt does TransMedics have?
TransMedics reported $512.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of TransMedics are outstanding?
TransMedics reported a weighted average of 34.6 million basic shares outstanding in 2026 Q2.
What is TransMedics' market cap?
Based on its latest closing price, TransMedics (TMDX) has a market capitalization of about $3.22B.
When does TransMedics' fiscal year end?
TransMedics' fiscal year end, as registered with the SEC, is December 31.
Where is TransMedics headquartered?
TransMedics lists its business address in Andover, Massachusetts in its SEC filings.